Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed triple-negative (estrogen, progesterone, and HER-2 receptor negative) adenocarcinoma of the breast in pre- or post-menopausal women with measurable or non-measurable metastatic disease
Participant who in the Investigator's opinion requires combination therapy for their disease
Life expectancy of greater than or equal to (\>/=)12 weeks
You may not be if
Previous chemotherapy for metastatic breast cancer
Participants currently undergoing radiation therapy for the treatment of metastatic disease (apart from the relief of metastatic bone pain)
Major surgery or significant traumatic injury within 28 days prior to enrollment or anticipation of the need for major surgery during study treatment
Clareo Health | A Study of Bevacizumab With Taxane Therapy in Participants With Triple Negative Breast Cancer
